They mimic the effects of endogenous GLP-1, which is produced in the intestines in response to food intake, and by activating the GLP-1 receptor they enhance glucose-dependent insulin secretion, inhibit glucagon release, and slow gastric emptying
And when it does come, those are the areas that wed love for physicians to know about now. A Perfect Storm of Risk Factors Lyddys concern is grounded in a convergence of factors that are difficult to ignore
Yes, it really is that important
Boehringer Ingelheim International GmbH Boehringer Ingelheim invests in innovative peptide research and collaborates on GLP-1 related compounds, focusing on improving treatment outcomes for metabolic disorders
These receptors in other areas of the body make it promising to use GLP-1s and similar drugs to treat other conditions, says Isaacs
doi: 10.7180/kmj.2021.36.1.1